+91 80 2808 2808
Biocon Biologics  /  Committed to ESG


Our philosophy of unconditional equity aims to ensure the well-being of our patients, people, partners, customers, shareholders, community and the ecosystem at large.

Over the years, we have built a strong, affordable innovation model, which has enabled us to lower the cost of life-saving biologic therapies and bring them within the reach of people suffering from chronic diseases like diabetes, cancer and autoimmune conditions.

While we pursue our purpose of using biotechnology to develop therapies that heal the world, we are equally concerned about the health of our planet and the depleting ecological balance.

As a responsible corporate citizen, we have designed our operations to enable environmental sustainability with a low carbon footprint, maximum recycling of wastewater and use of green power.

Supporting environmental and health equity is our commitment to diversity and inclusion at the workplace. We have consistently endeavored to create a collaborative and empowering work culture, in pursuit of building businesses that make a meaningful social impact.

We have established globally benchmarked standards of governance to build an environment of trust, transparency and accountability necessary for fostering long-term investment, financial stability and business integrity, thereby supporting stronger growth and more inclusive societies.

Arun Chandavarkar

Dr. Arun Chandavarkar, Managing Director, Biocon Biologics

Transformational Progress in Action

“Our purpose to champion change and make a meaningful and tangible difference in the lives of our patients and our people, forms the basis of all our business decisions. To deliver on our purpose, we are committed to a sustainable and equitable future with a strong focus on employee wellbeing, enabling development in the community and minimizing our impact on the environment.”

Turning ESG Strategy into Action
Q&A With Dr. Arun Chandavarkar, Managing Director, Biocon Biologics

At Biocon Biologics, we strongly believe that healthcare must take many forms and should be accessible to all in a cost-effective way. Biologics have increasingly become the foundation of innovative therapies in modern medicine. Given the pipeline of therapies in clinical development, it is evident that biological therapies will continue to gain importance, if not dominate the market.

Biosimilars, which are follow-on biologics typically launched after the innovator molecules lose patent protection, have already demonstrated their ability to broaden access to several life-saving therapies, thus enabling patient equity. Having entered this segment more than 15 years ago, Biocon is a frontrunner in biosimilars today. As an industry pioneer, Biocon was amongst the first wave of companies to address the global need for biosimilars. Biocon Biologics, which is an independent subsidiary of Biocon with its management team, is leveraging strong science, global scale and its long experience in biopharmaceuticals to develop and manufacture several high-quality biosimilars for treating various chronic conditions for global patient population. We have developed several monoclonal antibodies and therapeutic proteins, which are significantly impacting cancer care worldwide. Our portfolio of affordable recombinant human insulin and insulin analogs is benefiting millions of people with diabetes globally. In FY22, we touched 5.3 million patients’ lives worldwide through our biosimilars portfolio for diabetes, oncology, and immunology.

Our expertise in product development and manufacturing has allowed us to build a pipeline of 20 biosimilar assets for the coming decade. We will continue to invest in R&D to develop quality biosimilars for high-value therapeutics, enabling wider patient access.

Diabetes is a worldwide NCD pandemic that affects nearly half a billion people. Unfortunately, ‘four out of five’ people with diabetes live in low- and middle-income countries (LMICs). Insulins help save the lives of millions of diabetes patients each year, yet millions are denied access to this life-saving therapy due to its prohibitive costs.

Despite the capital-intensive nature of insulin production, Biocon Biologics has succeeded in expanding access to insulin therapy in India and key global markets by pursuing an innovation strategy that is rooted in affordability. We have built one of the largest insulin manufacturing capacities in the world, which we are using to shift the access paradigm for insulins, worldwide.

Biocon Biologics, through its proprietary Pichia pastoris platform, has been able to disrupt the insulins market globally. Our journey, which started with recombinant human insulin in India, has broadened to cover several global markets including the U.S. We have cumulatively supplied over 2.75 billion doses of recombinant human insulin to patients globally over the years.

Following the landmark commercialization of bGlargine in the U.S. in FY21, we marked another milestone by obtaining interchangeable designation from the U.S. FDA for our bGglargine in FY22. We are the first in the world to obtain approval for an interchangeable biosimilar product in the U.S. The interchangeability approval, which allowed substitution of our product for the innovator at the pharmacy counter, demonstrated our scientific, quality, and regulatory capabilities. The interchangeability status is allowing us to offer people living with diabetes in the U.S. more treatment options, rationalize cost of therapy and generate savings for the overall healthcare system. Our insulins are widening the treatment options available to patients living with diabetes, as well as enabling local healthcare systems to realize substantial savings on diabetes care. With the aim of making insulins affordable and accessible to patients in LMICs, we have rolled out our ‘Mission 10 cents’ initiative to supply recombinant human insulin at less than 10 U.S. cents per day to governments in some countries.

With the EU approval of our bAspart, we now have a broad portfolio, comprising basal, mixed and rapid acting insulins to meet the varied needs of people with diabetes worldwide.

Biocon Biologics has taken a modular approach to capacity expansion. As we progress on our strong growth trajectory, we will continue to invest in upgrading our facilities with new age technology and capabilities to ensure that we meet our global sustainability goals. Our new 340,000- square feet, monoclonal antibodies manufacturing facility received an honorable mention at the 2021 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE). This facility has been designed to be energy-efficient with green building design features, thus reducing our carbon footprint.

Conducting our business in the most responsible manner has always been in our DNA since inception. We continuously undertake initiatives across our facilities to ensure minimal environmental impact. We have been increasing the share of renewable energy across our operations through onsite solar installations and the procurement of wind energy. Further, we have adopted other innovative technologies like energy efficient centrifugal air compressors, water chillers and motors, and rooftop solar panels to reduce energy consumption, thereby, offsetting 63 percent of our total greenhouse gas emissions across Biocon Limited and Biocon Biologics.

Bio-manufacturing being a water-intensive industry, we have implemented targeted interventions to ensure all our manufacturing operations in India are Zero Liquid Discharge (ZLD) facilities equipped with advanced engineering systems to treat and reuse wastewater and effluents.

At Biocon Biologics, we believe synergistic collaborations can help us capitalize on each others strengths to deliver on our objective of enabling patient equity. Therefore, we have entered global partnerships for research, manufacturing, and commercialization. Our long-standing global partnership with Viatris has enabled us to achieve many firsts, setting new benchmarks for the global biosimilars industry. In FY22, we made a strategic decision to acquire the global biosimilars business of Viatris to create a fully integrated biosimilars business in Biocon Biologics. This deal provides several advantages, including expanded global footprint, direct-to-market access, strategic agility and operational efficiencies. Once concluded, this acquisition will enable us to expand patient access to biosimilars and reduce healthcare inequities worldwide.

During FY22, we also entered into a strategic alliance with Serum Institute Life Sciences (SILS) for vaccines to make a meaningful impact in fighting infectious
diseases. Vaccines and antibodies for infectious disease are a natural adjacency to Biocon Biologics’ existing capabilities in biologics for non-communicable diseases. Together with SILS, we believe we can address patients’ needs for vaccines for various infectious diseases, including COVID-19.

Our partnerships extend beyond our peers to include our vendors and consultants who have provided us with a continuous supply of raw materials, equipment as well as technical expertise when required. We are grateful for their efforts, which have enabled us to scale our operations and ensure business continuity, even in difficult times.

Our investor community has been vital in ensuring that we maintain a culture of transparency and accountability. We have received funding from four private equity investors and will be welcoming SILS and Viatris as shareholders post the completion of the two strategic deals, which I am sure will support us in building a world-class biosimilars company

Biocon Biologics’ workplace culture has been built on a strong sense of purpose and values.

It is designed to foster a healthy, happy and safe work environment where employees can fulfill their career aspirations while contributing to the organizational goals. We continuously strive to build a culture of transparency, openness, and innovation where people can find solutions to address patients’ needs.

Biocon Biologics continues to make investments for people development, in learning & training, mentoring & empowering and enabling their career growth, thereby accentuating their contribution to the biopharma industry. We pride ourselves on our people-centric approach. Our concern for the health and well-being of our employees is evident through the various employeeengagement initiatives, which have been recognized through several awards both nationally and internationally.

Diversity and inclusion are at the core of our business strategy as we believe that everyone has unique strengths which can be leveraged to create a culture of innovation at Biocon Biologics. Over the years we have focused on diversity hiring and have a large pool of women scientists who have partnered our science-led innovation journey. We take pride in having a merit-based work culture and have ensured gender parity in terms of compensation and benefits for similar roles. In order to ensure that women are well-represented in every team, we run special leadership development programs for women to take up larger roles.

The premise of carving out Biocon Biologics as an independent entity with its own professional management team and independent Board of Directors was not only to ensure undivided focus on the biosimilars business, but also ensure better governance. We have adopted globally benchmarked standards of governance to foster long-term investment, financial stability and business integrity, which enable sustained and equitable growth. Our ethical business practices have earned us a strong reputation and we continue to always uphold these through the highest level of compliance to our Code of Conduct and Ethics. We have put systems and processes in place at Biocon Biologics that support the anticipated growth in business while protecting the interests of our shareholders and other relevant stakeholders. In order to ensure consistent focus and drive our ESG strategy we have designed a robust multi-tiered governance framework at the Board, management and working group levels. As we bring global investors and new partners on board, we will uphold our firm commitment to ethics and values inherited from our parent company, Biocon Limited.